Key result
A first-time diagnosis of hyponatremia was associated with an increased risk of a subsequent cancer diagnosis compared to expected national rates.
Why the study?
Does a diagnosis of hyponatremia predict a subsequent cancer diagnosis in patients without prior cancer?
Cohort (n=16,220)
Yes
Does a diagnosis of hyponatremia predict a subsequent cancer diagnosis in patients without prior cancer?
A first-time diagnosis of hyponatremia is associated with a significantly increased risk of a subsequent cancer diagnosis, particularly within the first 6 months, suggesting it may serve as a marker for occult neoplasms.
Answers are grounded in this paper and cite their sources.
Hyponatremia may warrant cancer evaluation; leaves open whether screening protocols improve detection in observational data.
BACKGROUND: Hyponatremia has recently been associated with subsequent cancer risk. This population-based nationwide study assessed whether the diagnosis of hyponatremia can predict a cancer diagnosis within most common cancers. MATERIAL AND METHODS: Using Danish medical registries, we identified 16,220 patients with a first-time diagnosis of hyponatremia, without a cancer diagnosis, from January 2006 through November 2013. We quantified the relative risk of a subsequent cancer diagnosis by standardized incidence ratios (SIRs), comparing observed cancer incidence among patients diagnosed with hyponatremia to that expected, based on national cancer incidence during that period. RESULTS: During 40,207 person-years of follow-up, we observed 1546 cancer diagnoses compared to 956 expected (SIR: 1.62; 95% confidence interval (CI), 1.54-1.70). The increase in risk of a cancer diagnosis following a hyponatremia diagnosis was most pronounced within 0-6 months of follow-up (SIR 4.16; 95% CI, 3.85-4.48) and in the younger age group; 0-29 years (SIR 8.71; 95% CI, 2.82-20.28), 30-49 years (SIR 3.16; 95% CI, 2.26-4.31), 50-69 years (SIR 2.29; 95% CI, 2.10-2.48) and 70 + years (SIR 1.35; 95% CI, 1.27-1.44). Within six months after a hyponatremia diagnosis, the SIRs increased 10-fold for cancers of the lung (SIR 17.14; 95% CI, 15.15-19.32), brain (SIR 13.52; 95% CI, 8.90-19.66) and liver (SIR 13.26; 95% CI, 7.57-21.53) and increased 5 to 10-fold for cancers of the pancreas (SIR 8.25; 95% CI, 5.72-11.53), esophagus (SIR 6.59; 95% CI, 3.15-12.12), kidney (SIR 6.36; 95% CI, 3.39-10.88), pharynx (SIR 6.15; 95% CI, 1.27-17.97) and non-Hodgkin lymphoma (SIR 6.10; 95% CI, 4.17-8.61). The rate increased across virtually all types of cancers, except melanoma and basal cell carcinomas. CONCLUSIONS: A diagnosis of hyponatremia may be a marker of occult neoplasms, especially cancers of the lung, brain, liver, pancreas, esophagus, kidney, pharynx and non-Hodgkin lymphoma. Hyponatremia may aid in early detection of cancer.
No takes yet. Share an insight, caveat, or question.
Holland-Bill et al. (2017) conducted a cohort in Hyponatremia without prior cancer (n=16,220). First-time diagnosis of hyponatremia vs. Expected cancer incidence based on national rates was evaluated on Subsequent cancer diagnosis (SIR 1.62, 95% CI 1.54-1.70). A first-time diagnosis of hyponatremia was associated with an increased risk of a subsequent cancer diagnosis compared to expected national rates.
Synapse has enriched 10 related papers. Consider them for comparative context: